July 31
IN THIS ISSUE / July 31, 2019
- Academy and NPF release new psoriasis phototherapy guidelines
- DW Insights and Inquiries: A metabolic pathway that may allow dermatologists to run rings around porokeratoses
- Having trouble finding diphenylcyclopropenone?
- Submit an abstract for the Gross and Microscopic Symposium
- Nominations sought for 2020 Academy election
Academy and NPF release new psoriasis phototherapy guidelines
The American Academy of Dermatology and National Psoriasis Foundation have released new guidelines of care for the management and treatment of psoriasis with phototherapy. View the psoriasis phototherapy guidelines.
The new guidelines are also discussed in a JAAD bonus issue of Dialogues in Dermatology. Benjamin Stoff, MD, highlights the importance of the systematic review of the medical literature and how these new guidelines can be used by dermatologists who care for psoriatic patients. The discussion covers multiple treatment modalities, including narrow-band UVB therapy, broad-band UVB therapy, PUVA treatment, and the use of novel targeted therapies in the disease, addressing practical considerations such as patient selection, comorbidities, and treatment side effects. Listen to this bonus Dialogues episode.
Guidelines currently in development in the AAD-NPF guideline series include: treatment and management of psoriasis in the pediatric and adolescent population, management and treatment of adult psoriasis using non-biologics, and topical therapy.
Related Content:
- Answer this week’s phototherapy-related Question of the Week
- Collaboration and diverse expertise strengthen clinical practice guidelines – Dermatology World (February 2019)
- For your patients: Psoriasis Resource Center
- Psoriasis and Psoriatic Arthritis patient pamphlet
“I know the variants of porokeratoses and can recite them as though I am the very model of a modern major general — Mibelli, linear, punctate, palmoplantar, DSAP (disseminated superficial actinic porokeratosis), superficial disseminated, immunosuppression-related, and porokeratosis ptychotropica. The problem is that I really do not understand the pathogenesis of the cornoid lamella(e), nor do I know how to treat them effectively. My residents have heard me tell patients that if porokeratoses could communicate, they would thumb their noses at us, laughing at our attempts to get rid of them.”
I am quoting myself from a commentary I wrote two years ago (Joining the fold: Squamous cell carcinoma complicating porokeratosis ptychotropica). Today, newer molecular techniques are increasing our comprehension of the porokeratoses, which may legitimately result in worthwhile therapies before I retire. Keep reading!
Having trouble finding diphenylcyclopropenone?
The AADA has recently become aware that dermatologists are having difficulty finding diphenylcyclopropenone (DPCP), a drug used to treat alopecia areata and molluscum contagiosum. DPCP is a bulk drug ingredient that is compounded and distributed to dermatologists via hospitals or compounding pharmacies.
The Professional Compounding Centers of America (PCCA), a supplier of bulk drug ingredients, is working with an FDA-registered manufacturer. PCCA can help physicians locate compounding pharmacies that have this bulk drug ingredient. Contact A.J. Day, PharmD, vice president of clinical services at the PCCA, at 800-331-2498 or ADay@pccarx.com.
Submit an abstract for the Gross and Microscopic Symposium
The Gross and Microscopic Dermatology Symposium provides an opportunity for a five-minute presentation of clinical and investigative studies of patients and their disease. Studies for consideration should focus on common diseases with unusual facets or unusual diseases with attendant teaching value. Selected applicants will present at the symposium during the Academy’s 2020 Annual Meeting in Denver.
A panel of judges will select a grand prize winner, who will receive complimentary registration for the 2021 Annual Meeting. Abstracts must be submitted by 5 p.m. (CST) Aug. 28, 2019.
Nominations sought for 2020 Academy election
Nominations for Officers, Directors, and Nominating Committee Member Representatives (West Region) are now being accepted through Oct 1. To view reference materials, submit a nomination and letter of support, visit staging.aad.org/aadnominations or email callfornominations@aad.org.
